Docetaxel for Injection/ Taxotere 80MG
Payment Type:
T/T,L/C
Incoterm:
FOB
Min. Order:
100000 Vials
Transportation:
Ocean,Land,Air

INDICATION: 1.1 Breast Cancer Docetaxel for Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel for Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with...

Add To Cart
Overview
Product Attributes

Model No.80mg

Supply Ability & Additional Information

TransportationOcean,Land,Air

Payment TypeT/T,L/C

IncotermFOB

INDICATION:

1.1 Breast Cancer

Docetaxel for Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy.

Docetaxel for Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.

1.2 Non-Small Cell Lung Cancer

Docetaxel for Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy.

Docetaxel for Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition.

1.3 Prostate Cancer

Docetaxel for Injection in combination with prednisone is indicated for the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer.

1.4 Gastric Adenocarcinoma

Docetaxel for Injection in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease.

1.5 Head and Neck Cancer

Docetaxel for Injection in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).


80MG


If you are a distributor, please inquire with us about product registration, importing and/or marketing our products in your country or region.

If you are a consumer, don't hesitate to contact us about more information for this product.

Mail consultation
Please feel free to give your inquiry in the form below.We will reply you in 24 hours.